Recall Z-2023-2024

Becton Dickinson & Co. · initiated May 7, 2024

Class II Open, Classified

Class II – products that might cause a temporary health problem or pose a slight threat of a serious nature

Product

BD SARS-CoV-2 Reagents for BD MAX" Systems. RT-PCR test to detect SARS-CoV-2 in nasal, nasopharyngeal, oropharyngeal swab specimens, and saliva specimens.

Codes / lots: Catalog No. 445003-01; UDI-DI: (01) 60382904450030 (17) 240803 (10) 3291356 (20) 01 (30) 1, (01) 60382904450030 (17) 241119 (10) 3291358 (20) 01 (30) 1, (01) 60382904450030 (17) 241217 (10) 3326001 (20) 01 (30) 1; Lot No. 3291356 (Exp. 8/3/24), 3291358 (Exp. 11/19/24), 3326001 (Exp. 12/17/24).

Reason for recall

Assays may produce false negative results due to decreased activity of the enzyme utilized in manufacturing.

FDA-determined cause: Component design/selection

Action taken

Consignees were mailed and/or emailed an URGENT: Medical Device Product Correction notification, dated 5/7/24. The notification instructs consignees to immediately inspect their inventory for affected devices and destroy them per the consignee's destruction process, ensure the notification is read and understood, disseminate the notification to among those in your organization and customers who should be made aware, and return the completed Response Form to BD by email to BDRC22@bd.com or by fax to 312-949-0438. Consignees with any complaints can call 1-844-823-5433 or email productcomplaints@bd.com; consignees with any recall related questions can email BDRC22@bd.com.

Details

Recall number
Z-2023-2024
Initiated
May 7, 2024
Posted by FDA
June 5, 2024
Product code
QJR – Reagents, 2019-Novel Coronavirus Nucleic Acid
Quantity
2,061 kits
Distribution
Domestic: Nationwide Distribution; Foreign: AU, BR, BE, CA, CO, & JP.
Recalling firm
Becton Dickinson & Co., Sparks, MD

Official FDA recall record